Prelude Therapeutics Inc (PRLD) Live Share Price, Invest From India

Prelude Therapeutics Inc Stock Performance

as on April 11, 2026 at 6:59 am IST

Day's Low
Day's High
$4.10
Day's Price Range
$4.62
$4.11
0.24%
Downside
12.41%
Upside
52 Week's Low
52 Week's High
$0.64
52-Week Price Range
$4.82
$4.11
84.32%
Downside
17.15%
Upside

Prelude Therapeutics Inc share price movements today

Previous Close: $4.40
Open: $4.43
Volume: 317.8K
Day's Low - High: $4.10 - $4.62
52 Week Low - High: $0.64 - $4.82

Prelude Therapeutics Inc Historical Returns

1 Month Return: + 7.09 %
3 Month Return: + 55.13 %
1 Year Return: + 476.11 %
3 Year Return: -46.46 %
5 Year Return: -88.43 %

Prelude Therapeutics Inc Stock Fundamentals & Key Indicators

Check Prelude Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$276.6M

EPS (TTM)

-1.11

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-101.6M

Revenue (TTM)

12.1M

Profit Margin

0.00%

Return On Equity TTM

-99.45%

Prelude Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Prelude Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Prelude Therapeutics Inc	SELL	$276.6M	-88.43%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$42.6B	133.02%	140.91	8.45%
Vertex Pharmaceuticals Incorporated	BUY	$113.6B	104.49%	29.16	32.94%
Beone Medicines Ltd	NA	$36.0B	NA	126.38	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$81.2B	57.6%	18.52	31.41%

Stock Returns calculator for Prelude Therapeutics Inc Stock including INR - Dollar returns

The Prelude Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Prelude Therapeutics Inc investment value today

Current value as on today

₹6,24,861

Returns

₹5,24,861

(+524.86%)

Returns from Prelude Therapeutics Inc Stock

₹4,78,873 (+478.87%)

Dollar Impact

₹45,988 (+45.99%)

Analyst Recommendation on Prelude Therapeutics Inc Stock

Based on 9 analysts

SELL

11.11%

Buy

44.44%

Hold

44.44%

Sell

Based on 9 analysts, 44.44% of analysts recommend a 'SELL' rating for Prelude Therapeutics Inc. Average target price of $5.17

Prelude Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Prelude Therapeutics Inc.

What analysts predicted

20.5%UPSIDE

Target Price

$5.17

Current Price

$4.11

Analyzed by

9 Analysts

Target

$5.17

Prelude Therapeutics Inc target price $5.17, a slight upside of 20.5% compared to current price of $4.11. According to 9 analysts rating.

Prelude Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Prelude Therapeutics Inc Stock has increased by 38% in the last 30 days, reflecting an upward trend in search activity.

Time period: March 13, 2026 to April 12, 2026

Change:38% versus previous 30 day period

Prelude Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	3	-	-	3	4	-	-	6	5
Gross Profit	0	0	0	0	3	4	0	0	6	5
Operating Income	-33	-37	-34	-37	-34	-33	-34	-32	-20	-17
EBITDA	-33	-32	-33	-36	-33	-33	-34	-31	-19	-16
Interest Expense	-	1	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-30	-33	-31	-34	-32	-28	-32	-31	-19	-16
Income Tax Expense	0	1	0	-	-	-	-	-	-	-
Net Income	-30	-33	-31	-34	-32	-28	-32	-31	-19	-16
Net Profit Margin	0.00%	-965.98%	0.00%	0.00%	-1075.70%	-718.28%	0.00%	0.00%	-303.46%	-291.79%

Prelude Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	7	12
Gross Profit	0	0	0	-2	-3	-1	7	10
Operating Income	-14	-28	-58	-113	-123	-132	-139	-104
EBITDA	-14	-27	-58	-112	-122	-131	-137	-102
Interest Expense	-	-	-	2	1	-	-	-
Depreciation	0	0	0	0	1	1	1	1
Income Before Tax	-14	-27	-56	-111	-115	-121	-127	-99
Income Tax Expense	0	0	0	0	-8	0	-	-
Net Income	-14	-27	-56	-110	-107	-121	-127	-99
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1816.76%	-819.59%

Prelude Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-33	-31	-34	-32	-28	-32	-31	-19	-16
Operating Cash Flow	-23	-31	-23	-27	-20	-34	-26	-19	23
Investing Cash Flow	7	31	26	10	22	62	11	40	-60
Financing Cash Flow	25	0	0	0	0	0	0	0	24
Change in Cash	9	0	3	-16	1	27	-14	21	-12

Prelude Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-27	-56	-111	-115	-121	-127	-99
Operating Cash Flow	-25	-46	-83	-83	-107	-102	-56
Investing Cash Flow	0	0	-263	81	-34	90	53
Financing Cash Flow	29	246	164	0	136	0	24
Change in Cash	3	199	-182	-1	-5	-12	21

Global Institutional Holdings in Prelude Therapeutics Inc

Funds	Holdings
Royal Bank of Canada	0.01%
Baker Bros Advisors LP	16.07%
Morgan Stanley - Brokerage Accounts	0.45%
Susquehanna International Group, LLP	0.22%
Jane Street Group LLC	0.18%

See all

Prelude Therapeutics Inc News & Key Events

Insights on Prelude Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, PRLD has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 6 months, PRLD stock has moved up by 223.8%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 58.8% return, outperforming this stock by 105.7%

About Prelude Therapeutics Inc

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.

Organisation	Prelude Therapeutics Inc
Headquarters	175 Innovation Boulevard, Wilmington, DE, United States, 19805
Industry	Health Technology
CEO	Dr. Krishna Vaddi D.V.M., Ph.D.
E-voting on shares	Click here to vote

Key Management of Prelude Therapeutics Inc

Name	Title
Dr. Andrew P. Combs Ph.D.	Executive VP & Chief Chemistry Officer
Mr. Naveen Babbar Ph.D.	Senior Vice President of Translation Medicine
Dr. Wan-Jen Hong M.D.	Senior Vice President of Clinical Development
Dr. Krishna Vaddi D.V.M., Ph.D.	Founder, CEO & Director
Dr. Madhu Pudipeddi Ph.D.	Senior Vice President of Technical Operations
Mr. Robert A. Doody Jr.	Senior Vice President of Investor Relations
Ms. Michele Porreca M.B.A.	Chief People Officer
Mr. Bryant David Lim J.D.	CFO & Chief Legal Officer
Ms. Aimee Crombie Ph.D.	Senior VP and Head of Strategic Planning & Operations
Dr. Peggy A. Scherle Ph.D.	Chief Scientific Officer

FAQs

What is Prelude Therapeutics Inc share price today?

Prelude Therapeutics Inc share price today is $4.11 as on April 11, 2026 at 1:29 am IST at the close of the market. Prelude Therapeutics Inc share today touched a day high of $4.62 and a low of $4.1.

What is the 52 week high and 52 week low for Prelude Therapeutics Inc share?

Prelude Therapeutics Inc share touched a 52 week high of $4.82 on April 8, 2026 and a 52 week low of $0.64 on April 11, 2025. Prelude Therapeutics Inc stock price today i.e. April 11, 2026 at 1:29 am IST is closed at $4.11,which is 14.64% down from its 52 week high and 537.70% up from its 52 week low.

What is Prelude Therapeutics Inc's market capitalisation today?

Prelude Therapeutics Inc market capitalisation is $0.00T as on April 11, 2026 at 1:29 am IST.

How to invest in Prelude Therapeutics Inc Stock (PRLD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Prelude Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Prelude Therapeutics Inc Shares that will get you 0.3650 shares as per Prelude Therapeutics Inc share price of $4.11 per share as on April 11, 2026 at 1:29 am IST.

What is the minimum amount required to buy Prelude Therapeutics Inc Stock (PRLD) from India?

Indian investors can start investing in Prelude Therapeutics Inc (PRLD) shares with as little as ₹93.048 or $1 (as of April 12, 2026 at 7:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹930.48 in Prelude Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on April 12, 2026 at 7:40 am IST). Based on Prelude Therapeutics Inc share’s latest price of $4.11 as on April 11, 2026 at 1:29 am IST, you will get 2.4331 shares of Prelude Therapeutics Inc. Learn more about fractional shares .

What are the returns that Prelude Therapeutics Inc has given to Indian investors in the last 5 years?

Prelude Therapeutics Inc stock has given -88.43% share price returns and 23.46% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?